Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BDX
stocks logo

BDX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
5.15B
-0.34%
2.809
-18.11%
5.53B
+4.83%
3.368
+0.53%
5.73B
+3.99%
3.968
+7.82%
Estimates Revision
The market is revising Downward the revenue expectations for Becton, Dickinson and Company (BDX) for FY2026, with the revenue forecasts being adjusted by -1.55% over the past three months. During the same period, the stock price has changed by 1.31%.
Revenue Estimates for FY2026
Revise Downward
down Image
-1.55%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+0.12%
In Past 3 Month
Stock Price
Go Up
up Image
+1.31%
In Past 3 Month
Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 193.71 USD with a low forecast of 183.00 USD and a high forecast of 210.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 193.71 USD with a low forecast of 183.00 USD and a high forecast of 210.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
5 Hold
0 Sell
Moderate Buy
Current: 193.760
sliders
Low
183.00
Averages
193.71
High
210.00
Current: 193.760
sliders
Low
183.00
Averages
193.71
High
210.00
Morgan Stanley
Patrick Wood
Overweight
maintain
$197 -> $210
2025-12-02
New
Reason
Morgan Stanley
Patrick Wood
Price Target
$197 -> $210
2025-12-02
New
maintain
Overweight
Reason
Morgan Stanley analyst Patrick Wood raised the firm's price target on Becton Dickinson to $210 from $197 and keeps an Overweight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
Stifel
Buy
downgrade
$224 -> $210
2025-11-07
Reason
Stifel
Price Target
$224 -> $210
2025-11-07
downgrade
Buy
Reason
Stifel lowered the firm's price target on Becton Dickinson to $210 from $224 and keeps a Buy rating on the shares following the company's Q4 report and below-consensus FY26 guidance. This "reset" potentially offers a "conservative setup," the analyst tells investors.
RBC Capital
Shagun Singh
Sector Perform
downgrade
$211 -> $202
2025-11-07
Reason
RBC Capital
Shagun Singh
Price Target
$211 -> $202
2025-11-07
downgrade
Sector Perform
Reason
RBC Capital analyst Shagun Singh lowered the firm's price target on Becton Dickinson to $202 from $211 and keeps a Sector Perform rating on the shares. The company's Q4 results came largely in-line with expectations as it issued preliminary results on 10/15 but delivered a 1% surprise on the bottom-line, the analyst tells investors in a research note. Becton Dickinson's FY26 guidance at low single digit growth was somewhat below consensus due to ongoing headwinds around Alaris comps, China, and vaccine reductions however, the firm added.
Piper Sandler
Jason Bednar
Neutral
downgrade
$200 -> $190
2025-11-07
Reason
Piper Sandler
Jason Bednar
Price Target
$200 -> $190
2025-11-07
downgrade
Neutral
Reason
Piper Sandler analyst Jason Bednar lowered the firm's price target on Becton Dickinson to $190 from $200 and keeps a Neutral rating on the shares. The firm notes the company reported Q4 results that included revenue of $5,890M/+3.9% organic year-over-year consistent with last month's pre-announcement but below where Street estimates sat ahead of the pre-release, while EPS finished at $3.96 vs. the pre-announced range of $3.91-$3.99.
RBC Capital
Sector Perform
initiated
$211
2025-09-24
Reason
RBC Capital
Price Target
$211
2025-09-24
initiated
Sector Perform
Reason
RBC Capital initiated coverage of Becton Dickinson with a Sector Perform rating and $211 price target. The firm believes Becton is positioning itself for a next phase of growth with the business separation in Q1 of 2026. It cites the company's "conservative" fiscal 2026 outlook with limited earnings growth until 2027 and more attractive opportunities elsewhere in medical technology for the neutral rating.
Morgan Stanley
NULL -> Overweight
maintain
$196 -> $197
2025-08-11
Reason
Morgan Stanley
Price Target
$196 -> $197
2025-08-11
maintain
NULL -> Overweight
Reason
Morgan Stanley raised the firm's price target on Becton Dickinson to $197 from $196 and keeps an Overweight rating on the shares after updating the firm's estimates to reflect Q2 earnings that came in above expectations.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Becton Dickinson and Co (BDX.N) is 12.96, compared to its 5-year average forward P/E of 18.80. For a more detailed relative valuation and DCF analysis to assess Becton Dickinson and Co 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
18.80
Current PE
12.96
Overvalued PE
21.92
Undervalued PE
15.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
14.86
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
16.97
Undervalued EV/EBITDA
12.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.41
Current PS
0.00
Overvalued PS
3.90
Undervalued PS
2.92
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 956.9% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

BDX News & Events

Events Timeline

(ET)
2025-12-04
07:00:00
Becton Dickinson and ChemoGLO Announce Strategic Collaboration
select
2025-11-17 (ET)
2025-11-17
07:04:31
Becton Dickinson's Onclarity HPV Assay and BD Viper Achieve WHO Prequalification
select
2025-11-06 (ET)
2025-11-06
09:29:46
Becton Dickinson Raises Quarterly Dividend by 1% to $1.05 per Share
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
02:00 AMNASDAQ.COM
Significant Thursday Options Trading: COHR, RGTI, BDX

  • Rigetti Computing Options Activity: Rigetti Computing Inc (RGTI) has seen a significant options volume of 195,914 contracts today, equating to about 19.6 million underlying shares, which is 44.9% of its average daily trading volume over the past month.

  • High Volume Put Option for RGTI: The $25 strike put option expiring on December 19, 2025, has particularly high activity, with 12,899 contracts traded, representing approximately 1.3 million underlying shares.

  • Becton, Dickinson & Co Options Activity: Becton, Dickinson & Co (BDX) has recorded an options volume of 11,780 contracts today, which corresponds to around 1.2 million underlying shares, making up 44.7% of its average daily trading volume over the past month.

  • High Volume Call Option for BDX: The $220 strike call option expiring on March 20, 2026, has seen notable trading with 11,250 contracts, representing about 1.1 million underlying shares.

[object Object]
Preview
7.5
12-04PRnewswire
BD Partners with ChemoGLO to Enhance Healthcare Safety in Hazardous Drug Testing
  • Strategic Collaboration: BD and ChemoGLO have formed a partnership to enhance hazardous drug contamination testing efficiency and accuracy in healthcare settings by integrating the rapid BD® HD Check System with ChemoGLO™'s liquid chromatography-tandem mass spectrometry analysis.
  • Rapid Testing: The BD® HD Check System provides preliminary results in just 10 minutes, while ChemoGLO™ delivers comprehensive quantitative reports within three to five days, enabling healthcare facilities to quickly identify and respond to potential contamination risks.
  • Safety Assurance: This collaboration not only enhances the safety of healthcare workers but also helps institutions better assess environmental safety through both qualitative and quantitative testing, aligning with recommendations from the 2020 consensus conference.
  • Industry Impact: The joint efforts of BD and ChemoGLO will elevate industry standards in hazardous drug management, further solidifying both companies' leadership positions in the medical technology sector.
[object Object]
Preview
3.5
12-03PRnewswire
BD Launches New Cell Analyzers Enhancing Real-Time Imaging Capabilities
  • Technological Innovation: BD's newly launched FACSDiscover™ A8 Cell Analyzers feature BD SpectralFX™ technology, enabling the analysis of over 50 characteristics of a single cell with optimal resolution and sensitivity, thereby advancing research in immunology and cancer immunotherapy.
  • Real-Time Imaging: The new devices are equipped with BD CellView™ Image Technology, allowing for high-speed imaging that reveals spatial and morphological insights, such as the location of proteins within a cell, significantly enhancing researchers' analytical capabilities.
  • Market Accessibility: The addition of three-laser and four-laser configurations allows more laboratories, particularly those with budget constraints in academia and biotech, to access industry-leading technology, with flexible financing options available to mitigate capital expenditure.
  • Ecosystem Integration: All configurations of the FACSDiscover™ A8 Cell Analyzers seamlessly integrate with BD FACSDiscover™ Cell Sorters and reagents, creating a comprehensive laboratory solution that further enhances laboratory efficiency and data management capabilities.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Becton Dickinson and Co (BDX) stock price today?

The current price of BDX is 193.76 USD — it has increased 0.1 % in the last trading day.

arrow icon

What is Becton Dickinson and Co (BDX)'s business?

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

arrow icon

What is the price predicton of BDX Stock?

Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 193.71 USD with a low forecast of 183.00 USD and a high forecast of 210.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Becton Dickinson and Co (BDX)'s revenue for the last quarter?

Becton Dickinson and Co revenue for the last quarter amounts to 5.89B USD, increased 8.35 % YoY.

arrow icon

What is Becton Dickinson and Co (BDX)'s earnings per share (EPS) for the last quarter?

Becton Dickinson and Co. EPS for the last quarter amounts to 1.71 USD, increased 24.82 % YoY.

arrow icon

What changes have occurred in the market's expectations for Becton Dickinson and Co (BDX)'s fundamentals?

The market is revising Downward the revenue expectations for Becton, Dickinson and Company (BDX) for FY2026, with the revenue forecasts being adjusted by -1.55% over the past three months. During the same period, the stock price has changed by 1.31%.
arrow icon

How many employees does Becton Dickinson and Co (BDX). have?

Becton Dickinson and Co (BDX) has 72000 emplpoyees as of December 05 2025.

arrow icon

What is Becton Dickinson and Co (BDX) market cap?

Today BDX has the market capitalization of 55.30B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free